Trinity Biotech (TRIB) Operating Leases (2019 - 2025)

Trinity Biotech has disclosed Operating Leases across 7 years of filings, most recently posting $10.6 million for Q2 2025.

• Operating Leases for Q2 2025 came in at $10.6 million, up 3.48% year-over-year; the trailing twelve-month figure through Jun 2025 was $10.6 million (up 3.48% YoY), and the FY2024 annual result was $10.5 million, down 3.63% from the prior year.
• Operating Leases came in at $10.6 million for Q2 2025 at Trinity Biotech, up from $10.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $13.9 million in Q4 2021 to a low of $9.7 million in Q3 2024.
• The 5-year median for Operating Leases is $10.9 million (2023), against an average of $11.3 million.
• Across the five-year window, Operating Leases decreased 16.42% in 2021 and rose 3.48% in 2025, its largest moves.
• Trinity Biotech's Operating Leases stood at $13.9 million in 2021, then decreased by 11.53% to $12.3 million in 2022, then decreased by 11.37% to $10.9 million in 2023, then fell by 3.63% to $10.5 million in 2024, then rose by 0.73% to $10.6 million in 2025.
• The last three Operating Leases figures came in at $10.6 million (Q2 2025), $10.5 million (Q4 2024), and $9.7 million (Q3 2024), per Business Quant data.